Stage 4, MYCN amplification, and stage 4 patients not receiving oral metronomic MT after CR/VGPR/PR were independent adverse prognostic factors for high-risk NB patients without ASCT or anti-GD2 antibodies therapy. Here, MYCN is linked to neuroblastoma.